

Electronic Supplementary Information (ESI)

Joana F. Campos,^a Marie-Christine Scherrmann^b and Sabine Berteina-Raboin^{a*}

^a*Institut de Chimie Organique et Analytique (ICOA)*
Université d'Orléans UMR-CNRS 7311,
BP 6759, rue de Chartres 45067 Orléans cedex 2, France. sabine.berteina-raboin@univ-orleans.fr

^b*Institut de Chimie Moléculaire et des Matériaux d'Orsay (ICMMO)*
Université Paris-Sud UMR CNRS 8182,
Bâtiment 420, 91400 Orsay, France. marie-christine.scherrmann@u-psud.fr

Electronic Supplementary Information (ESI)

TABLE OF CONTENTS

1. General Equipment and general conditions
2. General procedures, characterization and spectra

2A. Synthesis of Imidazo[1,2-*a*]pyridines

2A1. General procedure for the synthesis of 3a-e and characterization

2A2. Procedure for the synthesis of 5 and characterization

2A3. General procedure for the synthesis of 6a-f and characterization

2A4. Spectra of ^1H NMR, ^{13}C NMR and ^{19}F NMR

2B. Suzuki-Miyaura coupling reaction

2B1. General procedure for the synthesis of 9a-e-, 11a-e, 13, 15, 17a-e and characterization

2B2. Spectra of ^1H NMR, ^{13}C NMR and ^{19}F NMR

2C. Sonogashira-Hagihara coupling reaction

2C1. General procedure for the synthesis of 19a-c, 20, 22, 24a,b,d,e and characterization

2C2. Spectra of ^1H NMR, ^{13}C NMR and ^{19}F NMR

General Equipment and general conditions

All reagents were purchased from commercial suppliers and were used without further purification except for DMF, which was stored under argon and activated molecular sieves. The reactions were monitored by thin-layer chromatography (TLC) analysis using silica gel (60 F254) plates. Compounds were visualized by UV irradiation. Flash column chromatography was performed on silica gel 60 (230-400 mesh, 0.040-0.063 mm). Melting points (mp [°C]) were taken on samples in open capillary tubes and are uncorrected. ¹H and ¹³C NMR spectra were recorded on a Bruker DPX 250 (13C, 62.9 MHz), Bruker avance II 250.13 (13C, 63 MHz), Bruker avance 400.13 (13C, 101MHz), or on a Bruker avance III HD nanobay 400.13 (13C, 101 MHz). Chemical shifts are given in parts per million from tetramethylsilane (TMS) as internal standard. The following abbreviations are used for the proton spectra multiplicities: b: broad, s: singlet, d: doublet, t: triplet, q: quartet, p: pentuplet, m: multiplet. Coupling constants (J) are reported in hertz (Hz). Multiplicities were determined by the DEPT 135 sequence. Attributions of protons and carbons were made with the help of HSQC and HMBC 2D NMRs. Eudesmane numbering of carbons was used instead of the IUPAC numbering. Microwaves-assisted reactions were carried out in a Biotage Initiator microwave synthesis instrument and temperatures were measured by IR-sensor. High-resolution mass spectra (HRMS) were performed on a Maxis UHR-q-TOF mass spectrometer Bruker 4G with an electrospray ionisation (ESI) mode.

1. General procedures, characterization and spectra

2A. Synthesis of Imidazo[1,2-a]pyridines

2A1. General procedure for the synthesis of 3a-e and characterization

General procedure: 2-amino pyridine (1.062 mmol), bromoacetophenone (1.062 mmol) and NaHCO₃ (2.124 mmol) were dissolved in eucalyptol (2mL) and the reaction was stirred at 105°C for 22 h. After completion the mixture was allowed to cool to room temperature. Then H₂O was added and the aqueous phase was extracted with AcOEt (3x15 mL). The organic phase was dried (Mg₂SO₄), filtered and concentrated under reduced pressure. The crude product was purified by recrystallization with pentane.

2-phenylimidazo[1,2-a]pyridine (3a): White solid (171mg, 83%), m.p. 131-132°C. ¹H NMR (400 MHz, CDCl₃) δ6.80 (t, *J* = 6.8 Hz, 1H), 7.20 – 7.22 (m, 1H), 7.32 (t, *J* = 7.4 Hz, 1H), 7.44 (t, *J* = 7.6 Hz, 2H), 7.67 (d, *J* = 9.1 Hz, 1H), 7.86 (s, 1H), 7.95 (d, *J* = 7.3 Hz, 2H), 8.13 (d, *J* = 6.8 Hz, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ108.2(CH), 112.7(CH), 117.4(CH), 125.1(CH), 125.7(CH), 126.1(2xCH), 128.2(CH), 128.8(2xCH), 133.2(C), 145.3(C), 145.4 (C) ppm.

2-(4-chlorophenyl)imidazo[1,2-a]pyridine (3b): White solid (192mg, 79%), m.p. 206-208°C. ¹H NMR (400 MHz, CDCl₃) δ6.76 (t, *J* = 6.7 Hz, 1H), 7.13– 7.19 (m, 1H), 7.38 (d, *J* = 8.5 Hz, 2H), 7.60 (d, *J* = 9.1 Hz, 1H), 7.80 (s, 1H), 7.87 (d, *J* = 8.5 Hz, 2H), 8.07 (d, *J* = 6.8 Hz, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ108.2(CH), 112.6(CH), 117.5(CH), 124.9(CH), 125.6(CH), 127.3(2xCH), 128.9(2xCH), 132.3(C), 133.7(C), 144.7(C), 145.7 (C) ppm.

2-(4-fluorophenyl)imidazo[1,2-a]pyridine (3c): White solid (205mg, 91%), m.p. 166-168°C. ¹H NMR (400 MHz, CDCl₃) δ6.75 (t, *J* = 6.8 Hz, 1H), 7.13 (d, *J* = 34.6 Hz, 3H), 7.60 (d, *J* = 9.1 Hz, 1H), 7.77 (s, 1H), 7.86 – 7.95 (m, 2H), 8.07 (d, *J* = 6.7 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ107.8(CH), 112.5(CH), 115.5(CH), 115.7(CH), 117.5(CH), 124.8(CH), 125.6(CH), 127.7(CH), 130.0 (C), 144.9(CH), 145.7(C), 161.5(C), 163.9 (C) ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -114.2 ppm.

2-(4-nitrophenyl)imidazo[1,2-a]pyridine (3d): Yellow solid (160mg, 63%), m.p. 262-264°C. ¹H NMR (400 MHz, CDCl₃) δ6.85 (d, *J* = 13.5 Hz, 1H), 7.23 (d, *J* = 10.1 Hz, 1H), 7.66 (d, *J* = 9.2 Hz, 1H), 8.00 (s, 1H), 8.11 (d, *J* = 8.8 Hz, 2H), 8.16 (d, *J* = 6.8 Hz, 1H), 8.30 (d, *J* = 8.9 Hz, 2H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ109.9(CH), 113.2(CH), 118.0(CH), 124.2(2xCH), 125.6(CH), 125.8(CH), 126.4(2xCH), 140.2(C), 143.4(C), 146.1(C), 147.2 (C) ppm.

2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (3e): White solid (183mg, 77%), m.p. 134-136°C. ¹H NMR (400 MHz, CDCl₃) δ3.85 (s, 3H), 6.77 (d, *J* = 13.5 Hz, 1H), 6.97 (d, *J* = 8.8 Hz, 2H), 7.16 (d, *J* = 16.9 Hz, 1H), 7.64 (d, *J* = 9.1 Hz, 1H), 7.77 (s, 1H), 7.89 (d, *J* = 8.8 Hz, 2H), 8.10 (d, *J* = 6.8 Hz, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ55.3(CH), 107.2(CH), 112.5(CH), 114.2(2xCH), 117.2(CH), 124.7(CH), 125.5(CH), 126.1(C), 127.4(2xCH), 132.4(C), 145.4 (C), 159.7 (C) ppm.

2A2. Procedure for the synthesis of 5 and characterization

2,3-diphenylimidazol[1,2-a]pyridine (5): 2-phenylimidazol[1,2a]pyridine **3a** (0.515mmol), Bromobenzene (0.772 mmol), KOAc (2.059 mmol) and Pd(OAc)₂ (5mol%) were added and the reaction was stirred at 150°C for 24h. After completion the mixture was allowed to cool to room temperature. Then H₂O was added and the aqueous phase was extracted with AcOEt (3x15mL). The organic phase was dried (Mg₂SO₄), filtered and concentrated under reduced pressure. The crude product was purified by recrystallization with pentane. White solid (84mg, 60%), m.p. 147-149°C. ¹H NMR (400 MHz, CDCl₃) δ6.75 (t, *J* = 6.8 Hz, 1H), 7.20 – 7.24 (m, 1H), 7.28 – 7.32 (m, 3H), 7.47 – 7.57 (m, 5H), 7.68 – 7.70 (m, 3H), 7.98 (d, *J* = 6.9 Hz, 1H)ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ112.3 (CH), 117.5 (CH), 121.1 (C), 123.3 (CH), 124.7 (CH), 127.5 (CH), 128.1 (2xCH), 128.3 (2xCH), 144.8(C), 128.9 (CH), 129.5 (2xCH), 129.9 (C), 130.7 (2xCH), 134.1 (C), 142.4 (C) ppm.

2A3. General procedure for the synthesis of 6a-f and characterization

General procedure: 2-amino pyridine (1.062mmol), bromoacetophenone (1.062mmol) and NaHCO₃ (2.124mmol) were dissolved in eucalyptol (2mL) and the reaction was stirred at 105°C for 22h. Then, ArBr (1.594 mmol), KOAc (4.248 mmol) and Pd(OAc)₂ (5mol%) were added and the reaction was stirred at 150°C for 24h. After completion, the mixture was allowed to cool to room temperature. Then H₂O was added and the aqueous phase was extracted with AcOEt (3x15mL). The organic phase was dried (Mg₂SO₄), filtered and concentrated under reduced pressure. The crude product was purified by recrystallization with pentane.

2-(4-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine (6a): Yellow solid (298mg, 74%), m.p. 193-195°C. ¹H NMR (400 MHz, CDCl₃) δ3.80 (s, 6H), 3.96 (s, 3H), 6.64 (s, 2H), 6.76 (d, *J* = 12.6 Hz, 1H), 7.00 (d, *J* = 17.6 Hz, 2H), 7.21 (d, *J* = 15.7 Hz, 1H), 7.68 (d, *J* = 27.1 Hz, 3H), 7.97 (d, *J* = 6.9 Hz, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ56.3(2xCH), 61.0(CH), 107.6(2xCH), 112.4(CH), 115.1(CH), 115.3(CH), 117.5(CH), 120.7(C), 123.5(CH), 124.8(CH), 124.9(C), 129.5(CH), 129.6(CH), 130.2(C), 138.6(C), 141.2(C), 144.6(C), 154.3(C), 161.2(C), 163.6(C) ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -114.5 ppm. HRMS: calcd for C₂₂H₂₀FN₂O₃ [M+H]⁺ 379.1452, found 379.1450.

2-(4-fluorophenyl)-3-(p-tolyl)imidazo[1,2-a]pyridine (6b): Yellow solid (186mg, 58%), m.p. 123-125°C. ¹H NMR (400 MHz, CDCl₃) δ2.45 (s, 3H), 6.71 (t, *J* = 6.8 Hz, 1H), 6.96 (t, *J* = 8.7 Hz, 2H), 7.15 – 7.20 (m, 1H), 7.31 (t, *J* = 5.4 Hz, 4H), 7.64 (t, *J* = 7.1 Hz, 3H), 7.92 (d, *J* = 6.9 Hz, 1H) ppm. ¹³C NMR (100.6 MHz, CDCl₃) δ21.4(CH), 112.3(CH), 115.1(CH), 115.3(CH), 117.4(CH), 120.9(C), 123.4(CH), 124.7(CH), 126.5(C), 129.6(CH), 129.7(CH), 130.4(2xCH),

130.5(2xCH), 139.0(C), 141.3(C), 144.7(C), 161.1(C), 163.5 (C) ppm. ^{19}F NMR (376 MHz, CDCl_3) δ -114.2 ppm. HRMS: calcd for $\text{C}_{20}\text{H}_{16}\text{FN}_2$ $[\text{M}+\text{H}]^+$ 303.1292, found 303.1291.

2-(4-fluorophenyl)-3-(4-nitrophenyl)imidazo[1,2-a]pyridine (6c): Yellow solid (354mg, 100%), m.p. 201-203°C. ^1H NMR (400 MHz, CDCl_3) δ 6.85 (t, $J = 7.3$ Hz, 1H), 7.01 (d, $J = 8.7$ Hz, 2H), 7.26 – 7.34 (m, 1H), 7.56 (dd, $J = 8.8, 5.4$ Hz, 2H), 7.65 (d, $J = 8.8$ Hz, 2H), 7.72 (d, $J = 9.1$ Hz, 1H), 8.07 (d, $J = 6.9$ Hz, 1H), 8.37 (d, $J = 8.8$ Hz, 2H) ppm. ^{13}C NMR (100.6 MHz, CDCl_3) δ 113.2(CH), 115.5(CH), 115.7(CH), 118.0(CH), 118.6(C), 122.8(CH), 124.8(2xCH), 125.8(CH), 129.6(C), 130.2(CH), 130.3(CH), 131.0(2xCH), 136.5(C), 143.6(C), 145.7(C), 147.5(C), 164.0 (C) ppm. ^{19}F NMR (376 MHz, CDCl_3) δ -113.3 ppm. HRMS: calcd for $\text{C}_{19}\text{H}_{13}\text{FN}_3\text{O}_2$ $[\text{M}+\text{H}]^+$ 334.0986, found 334.0985.


2-(4-fluorophenyl)-3-phenylimidazo[1,2-a]pyridine (6d): White solid (224mg, 73%), m.p. 106-108°C. ^1H NMR (400 MHz, CDCl_3) δ 6.72 (t, $J = 6.8$ Hz, 1H), 6.96 (t, $J = 8.8$ Hz, 2H), 7.16 – 7.22 (m, 1H), 7.41 – 7.55 (m, 5H), 7.60 – 7.69 (m, 3H), 7.94 (d, $J = 6.9$ Hz, 1H) ppm. ^{13}C NMR (100.6 MHz, CDCl_3) δ 112.3(CH), 115.1(CH), 115.3(CH), 117.5(CH), 120.8(C), 123.3(CH), 124.8(CH), 129.0(CH), 129.6(2xCH), 129.7(CH), 129.8(CH), 130.3 (C), 130.7(2xCH), 141.5(C), 144.8(C), 161.1(C), 163.6 (C) ppm. ^{19}F NMR (376 MHz, CDCl_3) δ -114.6 ppm.

2-(4-fluorophenyl)-3-(thiophen-3-yl)imidazo[1,2-a]pyridine (6e): Yellow solid (206mg, 66%), m.p. 129-131°C. ^1H NMR (400 MHz, CDCl_3) δ 6.76 (t, $J = 6.8$ Hz, 1H), 6.99 (t, $J = 8.8$ Hz, 2H), 7.14 (d, $J = 4.9$ Hz, 1H), 7.18 – 7.22 (m, 1H), 7.46 (d, $J = 1.8$ Hz, 1H), 7.51 – 7.58 (m, 1H), 7.36 – 7.69 (m, 3H), 7.97 (d, $J = 6.9$ Hz, 1H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 112.4 (CH), 115.1 (CH), 115.4 (CH), 115.9 (C), 117.5(CH), 123.6 (CH), 124.8 (CH), 126.3 (CH), 127.3 (CH), 128.7 (CH), 129.6 (CH), 129.7 (CH), 130.3 (C), 142.1 (C), 144.9 (C), 161.2 (C), 163.7 (C) ppm. ^{19}F NMR (376 MHz, CDCl_3) δ -114.5 ppm. HRMS: calcd for $\text{C}_{17}\text{H}_{12}\text{FN}_2\text{S}$ $[\text{M}+\text{H}]^+$ 295.0700, found 295.0697.



3-(2-(4-fluorophenyl)imidazo[1,2-a]pyridin-3-yl)quinolone (6f): Yellow solid (292mg, 81%), m.p. 170-172°C. ^1H NMR (400 MHz, CDCl_3) δ 6.77 (t, $J = 6.8$ Hz, 1H), 6.93 (t, $J = 8.7$ Hz, 2H), 7.21 – 7.26 (m, 1H), 7.60 (dt, $J = 8.9, 4.7$ Hz, 3H), 7.69 (d, $J = 9.1$ Hz, 1H), 7.77 – 7.84 (m, 3H), 7.99 (d, $J = 6.9$ Hz, 1H), 8.17 (d, $J = 8.5$ Hz, 1H), 8.26 (d, $J = 1.9$ Hz, 1H), 8.88 (d, $J = 2.1$ Hz, 1H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 112.9(CH), 115.4(CH), 115.7(CH), 117.4(C), 117.8(CH), 122.9(CH), 123.1(C), 125.5(CH), 127.5(CH), 127.9(CH), 129.6(CH), 129.8(CH), 129.9(CH), 129.9(C), 130.5(CH), 137.4(CH), 143.2(C), 145.4(C), 147.7(C), 151.7(CH), 161.3(C), 163.8 (C) ppm. ^{19}F NMR (376 MHz, CDCl_3) δ -113.8 ppm. HRMS: calcd for $\text{C}_{22}\text{H}_{15}\text{FN}_3$ $[\text{M}+\text{H}]^+$ 340.1245, found 340.1244.

2A4. Spectra of ^1H NMR, ^{13}C NMR and ^{19}F NMR



2-phenylimidazol[1,2a]pyridine (3a)





2,3-diphenylimidazol[1,2-a]pyridine (5)




2-(4-chlorophenyl)imidazo[1,2-a]pyridine (3b)





2-(4-fluorophenyl)imidazo[1,2-a]pyridine (3c)









2-(4-nitrophenyl)imidazo[1,2-a]pyridine (3d)




2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (3e)





2-(4-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyridine (6a)








2-(4-fluorophenyl)-3-(p-tolyl)imidazo[1,2-a]pyridine (6b)







2-(4-fluorophenyl)-3-(4-nitrophenyl)imidazo[1,2-a]pyridine (6c)








2-(4-fluorophenyl)-3-phenylimidazo[1,2-a]pyridine (6d)








2-(4-fluorophenyl)-3-(thiophen-3-yl)imidazo[1,2-a]pyridine (6e)





3-(2-(4-fluorophenyl)imidazo[1,2-a]pyridin-3-yl)quinoline (6f)





2B. Suzuki-Miyaura coupling reaction

2B1. General procedure for the synthesis of 9a-e, 11a-e, 13, 15, 17a-e and characterization

General procedure: A mixture of chloro compound (50 mg), boronic acid (1.5 eq.), Pd(PPh₃)₄ (0.1 eq.) Na₂CO₃ or K₂CO₃ (2 eq.) in Eucalyptol (3 mL) was stirred at 100 °C for 14 - 24 h. The reaction was followed by TLC. After completion the reaction was then cooled to room temperature and the mixture was concentrated under vacuum. The solid obtained was purified by flash chromatography using a mixture of AcOEt/petroleum ether.

4-(p-tolyl)thieno[3,2-d]pyrimidine (9a): white solid (65 mg, 99%), m.p. 117-119 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.46 (s, 3H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.61 (d, *J* = 5.5 Hz, 1H), 8.01 (d, *J* = 5.5 Hz, 1H), 8.11 (d, *J* = 8.2 Hz, 2H), 9.27 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 21.5 (CH), 125.0 (CH), 127.9 (C), 128.5 (2xCH), 129.8 (2xCH), 134.5 (C), 136.0 (CH), 141.5 (C), 154.9 (CH), 160.0 (C), 162.0 (C) ppm. HRMS: calcd. for C₁₃H₁₁N₂S [M+H]⁺ 227.0637, found 227.0635.

4-(thieno[3,2-d]pyrimidin-4-yl)benzotrile (9b): white solid (48 mg, 69%), m.p. 213-215 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 5.5 Hz, 1H), 7.90 (d, *J* = 8.3 Hz, 2H), 8.10 (d, *J* = 5.5 Hz, 1H), 8.33 (d, *J* = 8.3 Hz, 2H), 9.34 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 114.6 (C), 118.1 (C), 125.2 (CH), 129.2 (2xCH), 132.8 (2xCH), 136.5 (CH), 141.3 (C), 155.0 (CH), 157.8 (C), 162.6 (C) ppm. HRMS: calcd. for C₁₃H₈N₃S [M+H]⁺ 238.0433, found 238.0430.

4-(3-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidine (9c): white solid (58 mg, 71%), m.p. 111-113 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, *J* = 5.5 Hz, 1H), 7.70 (t, *J* = 7.8 Hz, 1H), 7.81 (d, *J* = 7.8 Hz, 1H), 8.05 (d, *J* = 5.5 Hz, 1H), 8.37 (d, *J* = 7.8 Hz, 1H), 9.30 (s, 1H), 8.48 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 121.1 (d, *J* = 282.8 Hz, CF₃), 125.1 (CH), 125.6 (CH), 127.6 (CH), 128.0 (C), 129.6 (CH), 131.6 (CH), 131.6 (d, *J* = 40.4 Hz, CF), 136.4 (CH), 138.0 (C), 154.9 (CH), 158.3 (C), 162.4 (C) ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.75 ppm. HRMS: calcd. for C₁₃H₈F₃N₂S [M+H]⁺ 281.0355, found 281.0353.

4-(benzo[b]thiophen-2-yl)thieno[3,2-d]pyrimidine (9d): white solid (62 mg, 79%), m.p. 173-175 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.46(m, 2H), 7.62 (d, *J* = 5.5 Hz, 1H), 7.90 – 7.94 (m, 2H), 8.04 (d, *J* = 5.5 Hz, 1H), 8.26 (s, 1H), 9.23 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 122.6 (CH), 124.9 (CH), 125.0 (2xCH), 125.8 (C), 126.5 (CH), 126.8 (CH), 135.6 (CH), 140.0 (C), 141.2 (C), 141.9 (C), 153.9 (C), 154.5 (CH), 162.3 (C) ppm. HRMS: calcd. for C₁₄H₉N₂S₂ [M+H]⁺ 269.0202, found 269.0200.

4-(benzofuran-2-yl)thieno[3,2-d]pyrimidine (9e): white solid (42 mg, 64%), m.p. 145-147 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.32 (t, *J* = 7.5 Hz, 1H), 7.43 (t, *J* = 8.3 Hz, 1H), 7.58 (d, *J* = 5.5 Hz, 1H), 7.66 (d, *J* = 8.3 Hz, 1H), 7.72 (d, *J* = 7.8 Hz, 1H), 7.83 (s, 1H), 8.06 (d, *J* = 5.5 Hz, 1H), 9.23 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 110.0 (CH), 112.0 (CH), 122.5 (CH), 123.9 (CH), 124.4 (CH), 125.6 (C), 126.8 (CH), 127.9 (C), 137.4 (CH), 150.2 (C), 152.6 (C), 154.5 (CH), 155.9 (C), 162.5 (C) ppm. HRMS: calcd. for C₁₄H₉N₂OS [M+H]⁺ 253.0430, found 253.0428.

5-methyl-7-(p-tolyl)-[1,2,4]triazolo[1,5-a]pyrimidine (11a): white solid (47 mg, 71%), m.p. 116-118 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.46 (s, 3H), 2.74 (s, 3H), 7.05 (s, 1H), 7.38 (d, *J* = 8.1 Hz, 2H), 7.97 (d, *J* = 8.2 Hz, 2H), 8.44 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 21.6 (CH), 25.2 (CH), 109.5 (CH), 126.9 (C), 129.2 (2xCH), 129.6 (2xCH), 142.40 (C), 147.3 (C), 155.6 (CH), 156.2 (C), 165.0 (C) ppm.

4-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)benzonitrile(**11b**): white solid (31 mg, 44%), m.p. 262-264 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.80 (s, 3H), 7.12 (s, 1H), 7.89 (d, *J* = 8.4 Hz, 2H), 8.22 (d, *J* = 8.4 Hz, 2H), 8.49 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 25.3 (CH), 110.4 (CH), 115.3 (C), 117.8 (C), 129.9 (2xCH), 132.6 (2xCH), 133.9 (C), 145.0 (C), 156.0 (CH), 165.4 (C) ppm.

5-methyl-7-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidine(**11c**): white solid (43 mg, 52%), m.p. 148-150 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.78 (s, 3H), 7.13 (s, 1H), 8.47 (s, 1H), 7.73 (t, *J* = 8.1 Hz, 1H), 7.86 (d, *J* = 7.9 Hz, 1H), 8.30 – 8.33 (m, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 25.2 (CH), 110.2 (CH), 123.6 (d, *J* = 272.7 Hz, CF₃), 126.2 (CH), 128.3 (CH), 129.5 (CH), 130.6 (C), 131.6 (d, *J* = 30.3 Hz, CF), 132.5 (CH), 145.5 (C), 155.9 (CH), 156.1 (C), 165.3 (C) ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.81 ppm. HRMS: calcd. for C₁₃H₁₀F₃N₄ [M+H]⁺ 279.0852, found 279.0850.

5-methyl-7-(thiophen-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidine(**11d**): yellow solid (31 mg, 48%), m.p. 135-137 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.74 (s, 3H), 7.21 (s, 1H), 7.51 (dd, *J* = 3.0, 5.2 Hz, 1H), 7.78 (dd, *J* = 1.3, 5.2 Hz, 1H), 8.50 (s, 1H), 9.04 (dd, *J* = 1.3, 3.0 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 25.2 (CH), 107.8 (CH), 126.6 (CH), 126.8 (CH), 129.9 (C), 132.6 (CH), 141.3 (C), 155.6 (CH), 156.2 (C), 164.8 (C) ppm. HRMS: calcd. for C₁₀H₉N₄S [M+H]⁺ 217.0542, found 217.0539.

7-(benzofuran-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine(**11e**): white solid (42 mg, 56%), m.p. 207-209 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.79 (s, 3H), 7.32 – 7.36 (m, 1H), 7.45 – 7.50 (m, 1H), 7.59 (d, *J* = 9.2 Hz, 2H), 7.76 (d, *J* = 7.8 Hz, 1H), 8.56 (s, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 25.3 (CH), 106.4 (CH), 111.6 (CH), 116.5 (CH), 123.1 (CH), 124.1 (CH), 127.9 (CH), 128.2 (C), 136.5 (C), 144.1 (C), 155.5 (C), 155.8 (CH), 155.8 (C), 164.7 (C) ppm. HRMS: calcd. for C₁₄H₁₁N₄O [M+H]⁺ 251.0927, found 251.0926.

8-(*p*-tolyl)-[1,2,4]triazolo[4,3-*a*]pyrazine(**13**): white solid (50 mg, 74%), m.p. 208-210 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.46 (s, 3H), 7.38 (d, *J* = 8.1 Hz, 2H), 7.99 (q, *J* = 4.6 Hz, 2H), 8.76 (d, *J* = 8.3 Hz, 2H), 8.96 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 21.6 (CH), 114.3 (CH), 128.9 (CH), 129.4 (2xCH), 129.7 (CH), 130.0 (CH), 131.9 (C), 136.1 (CH), 142.3 (C), 144.2 (C), 150.9 (C) ppm. HRMS: calcd. for C₁₂H₁₁N₄ [M+H]⁺ 211.0978, found 211.0976.

6-(*p*-tolyl)-[1,2,4]triazolo[4,3-*a*]pyrazine(**15**): white solid (46 mg, 68%), m.p. 242-244 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.42 (s, 3H), 7.31 (d, *J* = 7.9 Hz, 2H), 7.83 (d, *J* = 8.2 Hz, 2H), 8.38 (d, *J* = 1.6 Hz, 1H), 8.97 (s, 1H), 9.44 (d, *J* = 1.5 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 21.3 (CH), 111.0 (CH), 126.3 (2xCH), 129.9 (2xCH), 132.1 (C), 136.0 (CH), 139.8 (C), 140.8 (C), 143.3 (CH), 144.3 (C) ppm. HRMS: calcd. for C₁₂H₁₁N₄ [M+H]⁺ 211.0978, found 211.0977.

4-(*p*-tolyl)furo[3,2-*c*]pyridine (**17a**): white solid (44 mg, 65%), m.p. 122-124 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.44 (s, 3H), 7.06 – 7.08 (m, 1H), 7.34 (d, *J* = 7.9 Hz, 2H), 7.40 (d, *J* = 5.7 Hz, 1H), 7.68 (d, *J* = 2.2 Hz, 1H), 7.86 (d, *J* = 8.1 Hz, 2H), 8.57 (d, *J* = 5.7 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 21.4 (CH), 105.7 (CH), 105.9 (CH), 122.0 (C), 128.3 (2xCH), 129.4 (2xCH), 136.5 (C), 139.0 (C), 144.3 (CH), 145.4 (CH), 153.4 (C), 160.3 (C) ppm. HRMS: calcd. for C₁₄H₁₂NO [M+H]⁺ 210.0913, found 210.0908.

4-(furo[3,2-*c*]pyridin-4-yl)benzonitrile (**17b**): white solid (38 mg, 53%), m.p. 169-171 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.04 – 7.07 (m, 1H), 7.50 (d, *J* = 5.7 Hz, 1H), 7.77 (d, *J* = 2.3 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 8.09 (d, *J* = 8.4 Hz, 2H), 8.62 (d, *J* = 5.7 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 105.2 (CH), 106.9 (CH), 112.5 (C), 118.7 (C), 122.6 (C), 129.0 (2xCH), 132.5 (2xCH), 143.5 (C), 144.6 (CH), 146.4 (CH), 150.9 (C), 160.4 (C) ppm. HRMS: calcd. for C₁₄H₉N₂O [M+H]⁺ 221.0709, found 221.0709.



4-(3-(trifluoromethyl)phenyl)furo[3,2-c]pyridine (17c): white solid (84 mg, 98%), m.p. 89-91 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.04 – 7.07 (m, 1H), 7.48 (d, *J* = 5.7 Hz, 1H), 7.65 (t, *J* = 7.7 Hz, 1H), 7.70 – 7.76 (m, 2H), 8.15 (d, *J* = 7.7 Hz, 1H), 8.25 (s, 1H), 8.62 (d, *J* = 5.7 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 160.4 (C), 151.6 (C), 146.1 (CH), 144.5 (CH), 139.9 (C), 131.6 (CH), 131.2 (q, *J* = 32.59 Hz, C), 129.9 (C), 129.2 (CH), 125.6 (CH), 125.3 (CH), 124.1 (q, *J* = 272.7 Hz, C), 106.6 (CH), 105.4 (CH) ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.61 ppm. HRMS: calcd. for C₁₄H₉F₃NO [M+H]⁺ 264.0631, found 264.0629.

4-(thiophen-3-yl)furo[3,2-c]pyridine (17d): white solid (40 mg, 61%), m.p. 93-95 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.09 – 7.11 (m, 1H), 7.38 (d, *J* = 5.7 Hz, 1H), 7.46 (dd, *J* = 5.0, 3.0 Hz, 1H), 7.70 (d, *J* = 2.2 Hz, 1H), 7.77 (d, *J* = 5.0 Hz, 1H), 7.91 – 7.94 (m, 1H), 8.52 (d, *J* = 5.7 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 105.6 (CH), 105.8 (CH), 121.6 (C), 125.0 (CH), 126.2 (CH), 127.5 (CH), 141.3 (C), 144.2 (CH), 145.6 (CH), 148.7 (C), 160.3 (C) ppm. HRMS: calcd. for C₁₁H₈NOS [M+H]⁺ 202.0321, found 202.0319.



4-(benzofuran-2-yl)furo[3,2-c]pyridine (17e): white solid (53 mg, 69%), m.p. 105-107 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.23 – 7.28 (m, 1H), 7.32 – 7.37 (m, 1H), 7.38 (d, *J* = 5.6 Hz, 1H), 7.49 (d, *J* = 2.1 Hz, 1H), 7.60 (s, 2H), 7.66 (d, *J* = 7.7 Hz, 1H), 7.72 (d, *J* = 2.2 Hz, 1H), 8.54 (d, *J* = 5.6 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 106.3 (CH), 106.5 (CH), 106.6 (CH), 111.5 (CH), 121.3 (C), 121.9 (CH), 123.3 (CH), 125.4 (CH), 128.5 (C), 143.5 (C), 144.5 (CH), 146.0 (CH), 155.3 (C), 155.4 (C), 160.5 (C) ppm. HRMS: calcd. for C₁₅H₁₀NO₂ [M+H]⁺ 236.0706, found 236.0703.

2B2. Spectra of ¹H NMR, ¹³C NMR and ¹⁹F NMR



4-(*p*-tolyl)thieno[3,2-*d*]pyrimidine (9a)




4-(thieno[3,2-d]pyrimidin-4-yl)benzotrile (9b)





4-(3-(trifluoromethyl)phenyl)thieno[3,2-d]pyrimidine (9c)









4-(benzo[b]thiophen-2-yl)thieno[3,2-d]pyrimidine(9d)





4-(benzofuran-2-yl)thieno[3,2-d]pyrimidine (9e)





5-methyl-7-(p-tolyl)-[1,2,4]triazolo[1,5-a]pyrimidine (11a)




4-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)benzotrile(11b)





5-methyl-7-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidine(11c)









5-methyl-7-(thiophen-3-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (**11d**)





7-(benzofuran-2-yl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine (**11e**)





8-(*p*-tolyl)-[1,2,4]triazolo[4,3-*a*]pyrazine (13)




6-(*p*-tolyl)-[1,2,4]triazolo[4,3-*a*]pyrazine (15)





4-(p-tolyl)furo[3,2-c]pyridine (17a)




4-(furo[3,2-c]pyridin-4-yl)benzotrile (17b)





4-(3-(trifluoromethyl)phenyl)furo[3,2-c]pyridine (17c)






4-(thiophen-3-yl)furo[3,2-c]pyridine (17d)



4-(benzofuran-2-yl)furo[3,2-c]pyridine (**17e**)



2C. Sonogashira-Hagihara coupling reaction

2C1. General procedure for the synthesis of 19a-c, 20, 22, 24a,b,d,e and characterization

General procedure : A mixture of chloro compound (50 mg), acetylenes (1.5 eq.), Pd(PhCN)₂Cl₂ (0.1 eq.), P(Cy₃) (0.2 eq.), Cs₂CO₃ (2 eq.) in Eucalyptol (3 mL) was stirred at 100 °C for 16 - 36 h. The reaction was followed by TLC. After completion the reaction was then cooled to room temperature and the mixture was concentrated under vacuum. The solid obtained was purified by flash chromatography using a mixture of AcOEt/petroleum ether.

4-((4-methoxyphenyl)ethynyl)thieno[3,2-d]pyrimidine(19a): white solid (59 mg, 75%), m.p. 144-146 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.84 (s, 3H), 6.92 (d, *J* = 8.8 Hz, 2H), 7.55 (d, *J* = 5.5 Hz, 1H), 7.62 (d, *J* = 8.8 Hz, 2H), 8.00 (d, *J* = 5.5 Hz, 1H), 9.17 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 55.4 (CH), 84.5 (C), 98.8 (C), 112.8 (C), 114.3 (2xCH), 124.9 (CH), 132.8 (C), 134.3 (CH), 136.3 (CH), 145.8 (C), 154.7 (CH), 160.5 (C), 161.3 (C) ppm. HRMS: calcd. for C₁₅H₁₁N₂OS [M+H]⁺ 267.0587, found 267.0584.

3-(thieno[3,2-d]pyrimidin-4-ylethynyl)aniline(19b): yellow solid (60 mg, 81%), m.p. 149-151 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.81 (s, 2H), 6.76 (dd, *J* = 8.0, 2.1 Hz, 1H), 6.98 (s, 1H), 7.09 (d, *J* = 7.6 Hz, 1H), 7.19 (t, *J* = 7.8 Hz, 1H), 7.57 (d, *J* = 5.5 Hz, 1H), 8.02 (d, *J* = 5.5 Hz, 1H), 9.19 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 84.5 (C), 98.5 (C), 117.2 (CH), 118.3 (CH), 121.5 (C), 122.9 (CH), 124.9 (CH), 129.6 (CH), 133.2 (C), 136.5 (CH), 145.6 (C), 146.5 (C), 154.7 (CH), 160.6 (C) ppm. HRMS: calcd. for C₁₄H₁₀N₃S [M+H]⁺ 252.0590, found 252.0587.

4-((4-fluoro-3-methylphenyl)ethynyl)thieno[3,2-d]pyrimidine(19c): white solid (45 mg, 57%), m.p. 158-160 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.31 (s, 3H), 7.06 (t, *J* = 8.9 Hz, 1H), 7.54 (t, *J* = 6.7 Hz, 2H), 7.58 (d, *J* = 5.5 Hz, 1H), 8.04 (d, *J* = 5.5 Hz, 1H), 9.20 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 162.5 (d, *J* = 252.5 Hz, C), 160.7 (C), 154.8 (CH), 145.4 (C), 136.4 (CH), 135.9 (d, *J* = 5.9 Hz, CH), 133.0 (C), 132.1 (d, *J* = 8.8 Hz, CH), 125.9 (d, *J* = 18.4 Hz, C), 124.9 (CH), 116.6 (d, *J* = 3.8 Hz, C), 115.7 (d, *J* = 23.5 Hz, CH), 97.3 (C), 84.7 (C), 14.4 (CH) ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ -111.55 ppm. HRMS: calcd. for C₁₅H₁₀FN₂S [M+H]⁺ 269.0543, found 269.0541.

4-(thiophen-3-ylethynyl)thieno[3,2-d]pyrimidine(19d): yellow solid (60 mg, 84%), m.p. 94-96 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.39 (m, 2H), 7.59 (d, *J* = 5.5 Hz, 1H), 7.82 (dd, *J* = 2.8, 1.0 Hz, 1H), 8.04 (d, *J* = 5.5 Hz, 1H), 9.20 (s, 1H), ppm. ¹³C NMR (101 MHz, CDCl₃) δ 85.0 (C), 93.2 (C), 120.1 (C), 124.9 (CH), 126.1 (CH), 130.1 (CH), 132.4 (CH), 132.9 (C), 136.5 (CH), 145.5 (C), 154.7 (CH), 160.7 (C) ppm. HRMS: calcd. for C₁₂H₇N₂S₂ [M+H]⁺ 243.0045, found 243.0042.

4-(pyridin-3-ylethynyl)thieno[3,2-d]pyrimidine(19e): white solid (52 mg, 75%), m.p. 136-138 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.38 (dd, *J* = 4.9, 7.8 Hz, 1H), 7.61 (d, *J* = 5.5 Hz, 1H), 7.98 (dt, *J* = 1.8, 7.9 Hz, 1H), 8.07 (d, *J* = 5.5 Hz, 1H), 8.66 – 8.69 (m, 1H), 8.94 – 8.92 (m, 1H), 9.24 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 87.9 (C), 93.8 (C), 118.2 (C), 123.3 (CH), 125.0 (CH), 133.1 (C), 136.7 (CH), 139.3 (CH), 144.7 (C), 150.4 (CH), 153.0 (CH), 154.8 (CH), 161.0 (C) ppm. HRMS: calcd. for C₁₃H₈N₃S [M+H]⁺ 238.0433, found 238.0430.

7-((4-methoxyphenyl)ethynyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine (20): white solid (21 mg, 27%), m.p. 182-184 °C. ¹H NMR (400 MHz, CDCl₃) δ 2.70 (s, 3H), 3.86 (s, 3H), 6.94 (d, *J* = 8.8 Hz, 2H), 7.11 (s, 1H), 7.64 (d, *J* = 8.8 Hz, 2H), 8.51 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 25.0 (CH), 55.5 (CH), 104.5 (C), 112.0 (2xC), 113.6 (CH), 114.4 (3xCH), 131.0 (C), 134.5 (2xCH), 161.7 (2xC), 164.5 (C) ppm.

4-((4-methoxyphenyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidine (**22**): yellow solid (7 mg, 9%), m.p. 185-187 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.86 (s, 3H), 6.75 – 6.79 (m, 1H), 6.93 (d, *J* = 8.7 Hz, 2H), 7.42 (s, 1H), 7.63 (d, *J* = 8.6 Hz, 2H), 8.89 (s, 1H), 10.50 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 55.4 (CH), 85.1 (C), 96.4 (C), 100.9 (CH), 113.7 (C), 114.2 (2xCH), 119.7 (C), 126.0 (CH), 134.1 (2xCH), 143.0 (C), 151.3 (CH), 151.7 (C), 160.8 (C) ppm. HRMS: calcd. for C₁₅H₁₂N₃O [M+H]⁺ 250.0975, found 250.0974.

4-((4-methoxyphenyl)ethynyl)furo[3,2-c]pyridine (**24a**): yellow solid (38 mg, 47%), m.p. 91-93 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.84 (s, 3H), 6.91 (d, *J* = 8.8 Hz, 2H), 7.40 (d, *J* = 5.7 Hz, 1H), 7.01 (d, *J* = 2.0 Hz, 1H), 7.59 (d, *J* = 8.8 Hz, 2H), 7.69 (d, *J* = 2.2 Hz, 1H), 8.49 (d, *J* = 5.7 Hz, 1H) ppm. ¹³C NMR (63 MHz, CDCl₃) δ 55.4 (CH), 85.4 (C), 93.1 (C), 101.5 (C), 105.6 (CH), 106.6 (CH), 114.2 (2xCH), 126.7 (C), 133.8 (2xCH), 137.9 (C), 144.8 (CH), 145.8 (CH), 159.2 (C), 160.4 (C) ppm. HRMS: calcd. for C₁₆H₁₂NO₂ [M+H]⁺ 250.0863, found 250.0861.



3-(furo[3,2-c]pyridin-4-ylethynyl)aniline (**24b**): white solid (39 mg, 51%), m.p. 119-121 °C. ¹H NMR (400 MHz, CDCl₃) δ 3.75 (s, 2H), 6.71 (dd, *J* = 1.9, 7.6 Hz, 1H), 6.94 – 6.96 (m, 1H), 6.99 – 7.01 (m, 1H), 7.05 (d, *J* = 7.6 Hz, 1H), 7.15 (t, *J* = 7.8 Hz, 1H), 7.40 (d, *J* = 6.4 Hz, 1H), 7.68 (d, *J* = 2.2 Hz, 1H), 8.49 (d, *J* = 5.7 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 85.8 (C), 93.1 (C), 105.5 (CH), 106.8 (CH), 116.2 (CH), 118.2 (CH), 122.5 (CH), 122.8 (C), 127.0 (C), 129.4 (CH), 137.6 (C), 144.8 (CH), 146.0 (CH), 146.4 (C), 159.2 (C) ppm. HRMS: calcd. for C₁₅H₁₁N₂O [M+H]⁺ 235.0866, found 235.0864.

4-(thiophen-3-ylethynyl)furo[3,2-c]pyridine (**24d**): yellow solid (39 mg, 53%), m.p. 97-99 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.99 – 7.02 (m, 1H), 7.28 – 7.31 (m, 1H), 7.32 – 7.34 (m, 1H), 7.41 (d, *J* = 5.7 Hz, 1H), 7.68 – 7.69 (m, 2H), 8.49 (d, *J* = 5.7 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 86.2 (C), 87.8 (C), 105.5 (CH), 106.8 (CH), 121.3 (C), 125.6 (CH), 126.8 (C), 130.0 (CH), 130.4 (CH), 137.5 (C), 144.9 (CH), 146.0 (CH), 159.2 (C) ppm. HRMS: calcd. for C₁₃H₈NOS [M+H]⁺ 226.0321, found 226.0320.



4-(pyridin-3-ylethynyl)furo[3,2-c]pyridine (**24e**): yellow solid (27 mg, 38%), m.p. 111-113 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.01 (dd, *J* = 2.3, 1.0 Hz, 1H), 7.33 (dd, *J* = 7.9, 4.8 Hz, 1H), 7.46 (d, *J* = 5.6 Hz, 1H), 7.73 (d, *J* = 2.3 Hz, 1H), 7.92 (dt, *J* = 7.9, 2.0 Hz, 1H), 8.52 (d, *J* = 5.6 Hz, 1H), 8.60 (dd, *J* = 5.0, 1.8 Hz, 1H), 8.87 (d, *J* = 2.4 Hz, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 88.9 (C), 89.5 (C), 105.3 (CH), 107.3 (CH), 119.4 (C), 123.1 (CH), 127.2 (C), 136.7 (C), 138.9 (CH), 145.0 (CH), 146.3 (CH), 149.4 (CH), 152.6 (CH), 159.2 (C) ppm. HRMS: calcd. for C₁₄H₈N₂O [M+H]⁺ 221.0709, found 221.0707.

2C2. Spectra of ¹H NMR, ¹³C NMR and ¹⁹F NMR



4-((4-methoxyphenyl)ethynyl)thieno[3,2-d]pyrimidine(19a)




3-(thieno[3,2-d]pyrimidin-4-ylethynyl)aniline(19b)





4-((4-fluoro-3-methylphenyl)ethynyl)thieno[3,2-d]pyrimidine(19c)









4-(thiophen-3-ylethynyl)thieno[3,2-d]pyrimidine(19d)





4-(pyridin-3-ylethynyl)thieno[3,2-d]pyrimidine(19e)





7-((4-methoxyphenyl)ethynyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine(20)





4-((4-methoxyphenyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidine(22)




4-((4-methoxyphenyl)ethynyl)furo[3,2-c]pyridine (**24a**)



3-(furo[3,2-c]pyridin-4-ylethynyl)aniline (**24b**)



4-(thiophen-3-ylethynyl)furo[3,2-c]pyridine (24d)



4-(pyridin-3-ylethynyl)furo[3,2-c]pyridine (24e)

